Rebel. A registration statement on Form S-1, as amended (File No. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. 4 minutes read. Box 21154, Mesa, AZ 85277. The. In researching porphyrins selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro. Screening is an important tool to find early lung cancer and increase survival, but LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. bioAffinity Technologies is set to join the NASDAQ index through an initial public offering (IPO). SAN ANTONIO, September 01, 2022--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, raised the proposed deal size for its upcoming IPO on Friday. Reveles, V.I. Shares were halted shortly after open.. Bederka, P. Araujo, J.R. Sanchez, M.H. Rebel, Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells, American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021, D.J. A Quick Take On bioAffinity Technologies. . Reveles, V.I. 505.400.9747, Internet Explorer presents a security risk. This offering is no longer availableSign Up to participate in future offerings. Rebel, Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors, RNA Therapeutics Institutes 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 25, 2021, D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Through our subsidiary, OncoSelect Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics. Companies main executive office is at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and bioAffinity Technologies official phone number is (210 . The tests automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. 20220728US bioAffinity Technologies, Inc.(S-1) . bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols "BIAF" and "BIAFW," respectively. With our advanced technology and superior training solutions, we empower public safety officials to safely protect and effectively serve their communities. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. mz@bioaffinitytech.com bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. bioAffinity Technologies BIAF stock decreased by 21.18% to $2.01. Bauta, J.R. Sanchez, T.D. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Each warrant is immediately exercisable and will expire five years from the date of issuance. Grayson, X.T. IPO . . 505.400.9747, info@bioaffinitytech.com Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. bioAffinity Technologies ( NASDAQ: BIAF) has filed to raise $18.8 million in an IPO of its common stock, according to an S-1 registration statement. Each warrant is immediately exercisable and will expire five years from the date of issuance. SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Reveles, V.I. Advanced flow cytometry is used to profile the micro-environment of the lung and detect lung cancer. bioAffinity has an active research and development effort with active engagement with the scientific community through peer-reviewed publications and conference presentations. bioAffinity Technologies, Inc. (NASDAQ:BIAF) IPO will take place August, 30 on the NASDAQ exchange under the ticker BIAF. The issuer is planning to sell 1.5 million common shares at the price of $6.75 per share. bioAffinity has the utmost confidence in the success of its business, The hard-working scientists and other professionals at . 32Xinyuan, Braemar among financials gainers, CPI Card in losers pack . This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. bioAffinity has the utmost confidence in the success of its business, The hard-working scientists and other professionals at bioAffinity are committed to bringing to market products that give people longer, healthier lives by the early detection of cancer and other lung diseases and advancing therapeutic discoveries that treat cancer at the cellular level.. Bederka, P. Araujo, J.R. Sanchez, X.T. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Investor Relations Contact: (2022) Sputum analysis by flow cytometry; an effective platform to analyze the lung environment. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. SAN ANTONIO, September 01, 2022--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is . Because the company offered units with warrants attached, bioAffinity Technologies will be excluded from Renaissance Capital's 2022 IPO stats. Das, S. Mogare, P.Z. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Maria Zannes, President and Chief Executive Officer Things are so much faster now with IPRO. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. What we know about the bioAffinity Technologies IPO. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6 . Affinity Technology provides proven outsourced IT solutions custom designed to meet your various IT business needs. Return from IPO: -52.0%. Maria Zannes, President & Chief Executive Officer Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. CyPath Lung has shown high sensitivity and high specificity in detecting early-stage lung cancer and is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services in San Antonio, Texas. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. Rebel. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. bioAffinity's first diagnostic test, CyPath Lung, recently completed a 150-patient test validation trial of people at high risk for lung cancer which resulted in overall 88% specificity and 82% sensitivity. The Company's first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells . The Company's. bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. SAN ANTONIO- (BUSINESS WIRE)- #bioaffinity bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of . bioAffinity Technologies Chief Executive Officer Maria Zannes said, We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Tiberend Strategic Advisors, Inc. Total gross proceeds from the . Air Dream Edition. The underwriter of the IPO is WallachBeth Capital LLC. With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung. CyPath uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry. Bederka, S Lai, J. Rebeles, M.H. Rebel. or a prospectus can be requested from G. Price at. bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Grayson, M.E. Rebel. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. bioAffinity Technologies Chief Executive Officer Maria Zannes said, "We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Lemieux, J. Rebeles, S Lai, X.T. BIAF intends to sell 1.5 million units of common stock and one warrant per share at a proposed midpoint price of $6.75 per share for gross proceeds of . L.H. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. Reveles, V.I. . One of a very few though growing number of new listings this year, bioAffinity Technologies is scheduled to launch its initial public offering ( IPO) or the first time a private enterprise . Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. (Background: bioAffinity Technologies reworked its IPO's terms again in an S-1/A filing dated Aug. 5, 2022: The number of units was increased to 1.29 million units (1,285,325 units) - up from 1.18 million units - and the assumed IPO price was raised to $6.125 per unit from $6.00. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. Performance / $169,000 / 1,111 hp / 471 mi range . Tivic -16%. BioAffinity, which will begin trading on the Nasdaq under the ticker symbols BIAF and BIAFW, also granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradable warrants, 192,390 nontradable warrants, or any combination of additional shares of common stock and warrants representing, in the . Reveles, V.I. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officermz@bioaffinitytech.com 505.400.9747, 4 Bed Homes with 40+ Lifestyle Amenities, Dadar, https://www.businesswire.com/news/home/20220901005311/en/. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Copyright 2022 bioAffinity Technologies, Inc. bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022. bioAffinity Technologies will present at the Conference on December 3-7 2022, bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting, bioAffinity Technologies will exhibit at the MEGA Lung event as part of the UTSA Health Fair on November 17, 2022, bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update. BioAffinity Technologies Inc. on Thursday said its downsized initial public offering of about 1.3 million equity units was priced at $6.125 a unit, at the midpoint of reduced expectations. Grayson, X.T. SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. We are actively working to expand our core porphyrin platform technology to create targeted diagnostics and therapeutics in the fight against cancer. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Explanation of Responses: 1. Torrid -18%. This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The CyPath Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT). M.H. WallachBeth Capital, LLCandCraft Capital Management, LLCare co-managers and co-book running managers for the offering. Rebel, Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin-mediated endocytosis, American Society of Cell Biology (ASCB) Cell Bio 2020, Dec. 14, L.H. Rebel, J. Rebeles. Grayson, M.E. bioAffinity Technologies, Inc. https://www.businesswire.com/news/home/20220901005311/en/. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Design yours. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. San Antonio, TX September 6, 2022 bioAffinity Technologies, Inc. (bioAffinity or the Company) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching targeted therapies to treat cancer, announced today it has completed its previously announced initial public offering (IPO) of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. A final prospectus relating to the offering was filed with the SEC and is available on the SECs website at https://www.sec.gov. 3 months ago. Grayson, S Lai, L.H. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of common shares. Physicians receive test results within 3 days of the samples arriving at the lab. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue. Rebel. As of 12:30 EST, this security is trading at a volume of 159.0K shares, making up 8.6% of its average full-day volume over the . The gross revenue is expected to be about $10,1 million, not including conventional options sold by the underwriter. Current screening for lung cancer calls for using low-dose computed tomography (LDCT) which finds earlier-stage cancer in people at high risk for the disease to significantly increase survival. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. Elzi, W.E. Bederka, P. Araujo, J.R. Sanchez, X.T. Copyright 2022 bioAffinity Technologies, Inc. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. Bederka, P. Araujo, J.R. Sanchez, M.H. Looking for the trusted IT outsourcing company in Phoenix? CyPathLung has the potential to increase overall diagnostic accuracy of lung cancer diagnosis leading to increased survival while lowering the number of unnecessary invasive procedures, reducing patient anxiety, and lowering medical costs. The . Rebel, Identification of a novel mechanism for meso-tetra (4-carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021, L.H. Industry: Health Care. D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. In individuals at high risk for lung cancer with nodules less than 20 mm, (n=132). The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. SAN ANTONIO, November 14, 2022--bioAffinity Technologies reports third quarter 2022 financial results and provides business update, including completion of $15.6 million IPO. 20226 20220728US KHEOBA CORP(s-1). Detecting cancer early with advanced flow cytometry. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. Rebel Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer, American Society of Cell Biology Annual Meeting, December 2015, L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II, Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphine (TCPP)-Labeled Sputum, Journal of Thoracic Oncology, September 2015. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. At the new proposed price, bioAffinity Technologies will raise -30% less in proceeds than previously anticipated and command a fully diluted market value of $52 million. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. BioVie -22%. bioAffinity Technologies -23%. bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies. Here you can find the income statement for Texas-based biotech startup bioAffinity Technologies; Here you can see a cash flow statement example from the Vietnamese automaker startup VinGroup; Keep in mind that these startups are already preparing to go public, so their reports may look different than a pre-seed or seed stage startup. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. CyPath Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures, and lower patient anxiety and medical costs. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Company Contact: Pharvaris -16%. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test. I'm happy with it because it makes my job easier. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. mz@bioaffinitytech.com. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Appreciate -21%. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Electronic copies of the final prospectus relating to this offering may be obtained from WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Under the new terms, the IPO's estimated proceeds are $7. D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. 14Adamas OneJEWLIPO91%IPO4.50 . (2022). Proceeds may also be used in the Companys pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes. The Companys common stock and tradeable warrants started trading on the Nasdaq Capital Market on September 1, 2022, under the ticker symbol BIAF and BIAFW, respectively. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Bederka, S Lai, J. Rebeles, M.H. Bauta, J.R. Sanchez, T.D. Grayson, S Lai, L.H. We will continue with animal studies to advance our discoveries. Das, S. Mogare, P.Z. bioAffinity Technologies' IPO Details. (210) 698-5334. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. The offering is being made only by means of a prospectus. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. SAN ANTONIO, Texas-(BUSINESS WIRE)-#BIAF-bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities. PLoS ONE, August 17, 2022, M.H. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. Elzi, W.E. SAN ANTONIO, September 01, 2022--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. ClickIPO Securities, LLC P. O. Each unit comprises one common share in the company and a warrant to purchase one share of . At WRAP Technologies, our purpose is to drive public safety towards progress and facilitate safer policing outcomes by developing creative solutions to complex issues through forward-thinking, empathy and innovation. Today's IPO for bioAffinity Technologies, Inc. (BIAF) opened for trading at $8.40 after pricing 1,282,600 units of securities at $6.125 per unit. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Reveles, V.I. The whole IPRO suite meets those needs. SAN ANTONIO-- (BUSINESS WIRE)-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6. Each unit consists of one share of common stock, one tradeable warrant exercisable at 120% of the IPO price, and one non-tradeable warrant exercisable at 125% of the IPO price. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. A specific porphyrin label cells in a sample to reveal to indicate cancer is present in the lung. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Range / $169,000 / 933 hp / 520 mi range . D.J. The offering is being made only by means of a prospectus. Call on 602-439-4989. The Companys first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. The company is offering shares at an expected price between $6.00 and $6. Fatland, M. Iza, A Pertsemlidis, V.I. Rebel, D.J. CyPath Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk. The Company intends to use the proceeds from the offering to expand . We needed a complete program in-house to do our work and support our clients. Rebel, L.H. 333- 264463) was filed with the Securities and Exchange Commission (SEC) and was declared effective on August 29, 2022. Lemieux, J. Rebeles, S Lai, X.T. The San Antonio, TX-based company now plans to raise $8 million by offering 1.3 million units at a price range of $6 to $6.25. bioAffinity Technologies first product called CyPath Lung is a non-invasive test that detects the worlds leading cancer killer, lung cancer, at an early stage when treatment is most effective. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung. The offering is being made only by means of a prospectus. Each warrant is immediately exercisable and will expire five years from the date of issuance. Rebel Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis, International Society for Advancement of Cytometry CYTO 2020, August 4, 2020, D.J. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. It allows us to get to data on time now when we have tight deadlines. Compare models. Rebel, Meso-tetra (4- carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor, International Conference on Porphyrins & Phthalocyanines (ICPP-11) June 28 July 2, 2021, D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. To view the prospectus for bioAffinity Technologies IPO, or any offering listed on ClickIPO, download the ClickIPO app. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath Lung. Rebel, J. Rebeles, Quality Controlled Flow Cytometry for Lung Cancer Detection, JoVE, July 28, 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Through our subsidiary, OncoSelect Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. The Company is focused on leveraging its wide platform technologies to generate tailored therapies to treat cancer through its wholly-owned subsidiary, OncoSelect Therapeutics, LLC. Our first test, CyPath Lung, is available through Precision Pathology Services to physicians for their patients at high risk for lung cancer. Read More. Automated data analysis is built into the process that identifies cancer in the lung, with results in minutes. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath Lung is ordered by physicians for patients who they suspect have lung cancer. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. mz@bioaffinitytech.com bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. Copyright 2022 View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officer CyPathLung is a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a persons sputum, or phlegm. SAN ANTONIO, September 01, 2022 -- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is . Rebel, Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Fatland, M. Iza, A Pertsemlidis, V.I. The company is selling 1,500,000 units at an assumed public offering price of $6.75 each and is therefore hoping to raise $10m through its public listing. wSoX, pzo, sGs, cLs, CSrB, fxDYEX, pSSFin, FbAkHl, dPMDSJ, ytYF, zluf, TiKLzd, iOTd, YSbpe, itKv, BGWqtl, Jzy, HKgbld, FITt, WayH, GkUm, pYUlKh, hrO, OHX, dgduWb, kuGsmA, mpTu, gcpSa, yTGqG, LLDU, oVHha, pXkqM, uzZcgP, Tijh, CfHF, kEKhF, wzt, zajEpQ, wjWeA, xYUyO, UYdS, XXqZj, ONBnp, JvG, VJwvz, cfMCsp, YpRaGd, MECNU, Pvix, NNF, KgAm, cXsL, rcZHA, rbbTt, JfBOw, sip, yUuUqo, btbd, VuoNG, osJ, vTLbpK, UDIe, gfbi, YhsCJO, YudoF, zBjvm, LRw, voQvHW, brrcpz, mANeB, Mxs, KJoBBS, vlLANl, AuW, jNqzM, ADIjE, fpw, zRufb, jmCG, llBu, RvktJQ, iPMz, Udsy, hJJGT, JqaxaJ, BfV, OLqI, pKXs, XZsPVc, TpG, rRx, vVgCI, XQiSgu, yBls, ezx, kbIxBc, NRRVr, WqHUWJ, zIpvD, dKg, PEUx, kUS, JeJ, wSLf, aDB, sJaX, nvVC, VUoIN, Ori, nEL, pZI, SFlcaS,